Literature DB >> 34766299

Lipopeptide Pepducins as Therapeutic Agents.

Emily Michael1, Lidija Covic1, Athan Kuliopulos2.   

Abstract

Pepducins are lipidated peptides that target the intracellular loops of G protein-coupled receptors (GPCRs) in order to modulate transmembrane signaling to internally located effectors. With a wide array of potential activities ranging from partial, biased, or full agonism to antagonism, pepducins represent a versatile class of compounds that can be used to potentially treat diverse human diseases or be employed as novel tools to probe complex mechanisms of receptor activation and signaling in cells and in animals. Here, we describe a number of different pepducins including an advanced compound, PZ-128, that has successfully progressed through phase 2 clinical trials in cardiac patients demonstrating safety and efficacy in suppressing myonecrosis and arterial thrombosis.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atopic dermatitis; CAD; FPR; GPCRs; NASH; PAR1; PAR2; PZ-128; Pepducin; β2AR

Mesh:

Substances:

Year:  2022        PMID: 34766299     DOI: 10.1007/978-1-0716-1752-6_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  103 in total

1.  Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides.

Authors:  Lidija Covic; Amy L Gresser; Joyce Talavera; Steven Swift; Athan Kuliopulos
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.

Authors:  Paul A Gurbel; Kevin P Bliden; Susan E Turner; Udaya S Tantry; Martin G Gesheff; Travis P Barr; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01       Impact factor: 8.311

3.  β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.

Authors:  Richard Carr; Justin Schilling; Jianliang Song; Rhonda L Carter; Yang Du; Sungsoo M Yoo; Christopher J Traynham; Walter J Koch; Joseph Y Cheung; Douglas G Tilley; Jeffrey L Benovic
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-27       Impact factor: 11.205

Review 4.  Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection.

Authors:  Surovi Saikia; Manobjyoti Bordoloi; Rajeev Sarmah
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

Review 5.  Restructuring G-protein- coupled receptor activation.

Authors:  Martin Audet; Michel Bouvier
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

Review 6.  Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development.

Authors:  Katie O'Callaghan; Athan Kuliopulos; Lidija Covic
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

7.  PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models.

Authors:  Travis P Barr; Chris Garzia; Srijoy Guha; Elizabeth K Fletcher; Nga Nguyen; Adam J Wieschhaus; Lluis Ferrer; Lidija Covic; Athan Kuliopulos
Journal:  J Invest Dermatol       Date:  2018-10-01       Impact factor: 8.551

Review 8.  Trends in GPCR drug discovery: new agents, targets and indications.

Authors:  Alexander S Hauser; Misty M Attwood; Mathias Rask-Andersen; Helgi B Schiöth; David E Gloriam
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

9.  Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling.

Authors:  Laurel A Grisanti; Toby P Thomas; Rhonda L Carter; Claudio de Lucia; Erhe Gao; Walter J Koch; Jeffrey L Benovic; Douglas G Tilley
Journal:  Theranostics       Date:  2018-09-09       Impact factor: 11.556

10.  PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study.

Authors:  Athan Kuliopulos; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Susan E Turner; Kevin P Bliden; Elizabeth K Fletcher; Daniel H Cox; Lidija Covic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-08       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.